arrow
D

Dmitriy Zamarin

Memorial Sloan Kettering Cancer Center
H指数:57
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenomic determinants of response to immune checkpoint inhibition in ovarian cancer: Insights from the NRG-GY003 clinical trial

卵巢癌中免疫检查点抑制的免疫基因组学决定因素:NRG-GY003临床试验的启示

2026-04-230
PRE
Rethinking ovarian cancer III: the past decade and future directions

重新思考卵巢癌III:过去十年及未来方向

2026-04-130
PRE
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors

敏感CAR T细胞重新定义实体瘤中可靶向的CD70表达

Science
IF45.8
2026-02-260
PRE
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer

基于NRG GY017的局部晚期宫颈癌免疫治疗联合化疗放射治疗中的影像引导近距离放射治疗质量保证研究

2026-01-011
OAAI
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer

Thrombospondin-1-CD47信号有助于癌症中T细胞耗竭的发展

2025-11-170
PRE
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer

一项关于尼洛替尼与卵巢癌新诊断患者新辅助及术后化疗联合应用的试点研究

2025-10-310
PRE
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

使用细胞游离DNA追踪卵巢癌治疗过程中的克隆进化

Nature
IF48.5
2025-10-010
OA
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

正在进行的基因组加倍塑造卵巢癌的进化和免疫力

Nature
IF48.5
2025-07-160
OA
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era

2024年国家癌症研究所/妇科癌症指导委员会子宫内膜癌临床试验规划会议工作组报告:在免疫治疗时代完善子宫内膜癌的治疗方法

2025-04-110
PRE
Methylation Profiling of Small Cell Carcinoma Hypercalcemic Type (SCCOHT) Identifies Three Groups with Distinct Clinical and Morphological Characteristics

小细胞癌高钙血症型 (SCCOHT) 的甲基化谱分析可确定具有不同临床和形态特征的三组

2025-03-010
PRE
Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva

人乳头瘤病毒阴性外阴浸润性鳞状细胞癌的分子及微环境景观

2025-02-010
PRE
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity
2024-12-060
PRE
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
2024-07-172
OA
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
2024-04-234
OAAI
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
2024-04-051
PRE